Calprotectin Testing Market

Calprotectin Testing Market Size, Market Forecast and Outlook By FMI

The calprotectin testing market was valued at USD 51.1 billion in 2025. The market is set to reach USD 54.3 billion by 2026-end and grow at a CAGR of 6.1% between 2026-2036 to reach USD 98.1 billion by 2036. Calprotectin ELISA Test Kits will dominate with a 58.0% share, while Stool Samples will lead with a 82.0% share.

Key Takeaways, Market Size, and Forecast

• 2026 Market Size: USD 54.3 billion
• 2036 Market Size: USD 98.1 billion
• Compound Annual Growth Rate (CAGR): 6.1% from 2026 to 2036
• Absolute $ Opportunity: USD 43.8 billion between 2026 and 2036
• Leading Product Segment: Calprotectin ELISA Test Kits
• Calprotectin ELISA Test Kits Share in 2026: 58%
• Fastest-growing Country: USA
• USA CAGR: 6% through 2036

Parameter	Details
Market Size in 2026 (Value)	USD 54.3 billion
Market Forecast in 2036 (Value)	USD 98.1 billion
CAGR (2026 to 2036)	6.1%
Years Considered	2021 to 2036
Base Year	2025
Forecast Period	2026 to 2036
Units Considered	Value (USD Bn)
Leading Sub-Region	USA

Summary of the Calprotectin Testing Market

• Demand and Growth Drivers
  • Demand for calprotectin testing is expanding as gastroenterologists and primary care physicians adopt fecal calprotectin assays as a non-invasive biomarker for differentiating inflammatory bowel disease from irritable bowel syndrome, reducing unnecessary colonoscopy referrals.
  • Calprotectin ELISA test kits account for 58.0% of the product segment in 2026, reflecting their established position as the reference standard for quantitative fecal calprotectin measurement in clinical laboratory settings.
  • Point-of-care rapid test formats are gaining procurement traction as gastroenterology clinics and primary care practices seek faster turnaround times for initial patient screening and treatment monitoring.
• Product and Segment View
  • Calprotectin ELISA test kits hold 58.0% of the product segment in 2026, with quantitative immunoassay formats serving clinical laboratories and hospital diagnostic departments.
  • Healthcare providers account for 55.0% of the end use segment, with hospitals and gastroenterology clinics as primary buyers for calprotectin testing products and services.
  • IBD diagnosis and monitoring accounts for the largest application share, reflecting the clinical utility of calprotectin as a biomarker for inflammatory bowel disease activity assessment.
• Geography and Competitive Outlook
  • The USA leads at 6.0% CAGR, supported by clinical guideline adoption, health insurance coverage for fecal calprotectin testing, and expanding use in primary care and gastroenterology settings.
  • South Korea at 5.8% reflects growing adoption of non-invasive diagnostic biomarkers, expanding gastroenterology practice infrastructure, and health system modernization.
  • BUHLMANN Laboratories AG holds a leading competitive position as the originator of the fCAL calprotectin assay platform with established clinical validation and laboratory distribution.
• Analyst Opinion
  • Nandini Roy Choudhury, Principal Consultant at FMI says, 'Diagnostic companies that can deliver validated calprotectin assays with rapid turnaround, integration with laboratory information systems, and demonstrated clinical utility for IBD management are positioned to capture the expanding adoption of non-invasive gastrointestinal biomarker testing through 2036.'
  • The calprotectin testing market is evolving from specialized gastroenterology use to broader primary care adoption as clinical guidelines increasingly recommend fecal calprotectin as a first-line screening tool before colonoscopy referral.
  • Adoption of lateral flow rapid calprotectin tests is increasing due to clinic-based demand for point-of-care results that enable same-visit clinical decision-making.
  • Demand is further supported by the growing global prevalence of inflammatory bowel disease and the clinical need for non-invasive monitoring tools that track treatment response without repeated endoscopic procedures.

Calprotectin Testing Market Definition

The calprotectin testing market encompasses diagnostic assays, test kits, and point-of-care devices that measure fecal calprotectin levels as a biomarker for intestinal inflammation. Products include ELISA kits, rapid lateral flow tests, automated immunoassay platforms, and laboratory testing services used for IBD diagnosis, treatment monitoring, and differential diagnosis of gastrointestinal symptoms.

Calprotectin Testing Market Inclusions

Market scope covers all commercially traded calprotectin testing products and services categorized by product, sample, application, technology, end use, distribution channel. Revenue is tracked from 2026 to 2036.

Calprotectin Testing Market Exclusions

The scope does not include general stool analysis tests that do not specifically measure calprotectin, serum C-reactive protein tests used for systemic inflammation assessment, or endoscopic procedures for direct intestinal visualization.

Calprotectin Testing Market Research Methodology

• Primary Research: FMI analysts conducted interviews with diagnostic manufacturers, gastroenterology practice managers, clinical laboratory directors, and health insurance formulary committees.
• Desk Research: Combined data from clinical guideline organizations, diagnostic testing regulatory databases, and gastroenterology practice surveys.
• Market Sizing and Forecasting: Bottom-up aggregation from test kit sales volumes, laboratory testing service revenues, and point-of-care device deployments with regional clinical adoption projections.
• Data Validation: Cross-checked quarterly against diagnostic product shipment data, laboratory test volume statistics, and clinical practice guideline adoption rates.

Why is the Calprotectin Testing Market Growing?

• Clinical guideline adoption recommending fecal calprotectin as a first-line non-invasive screening tool for differentiating IBD from IBS is the primary demand driver, reducing colonoscopy referral rates and enabling earlier treatment initiation.
• The USA leads at 6.0% CAGR, supported by AGA and ACG guideline endorsement, health insurance coverage expansion, and growing primary care utilization of calprotectin testing as a GI screening tool.

The calprotectin testing market is expanding at 6.1% CAGR from 2026 to 2036, reflecting broadening clinical adoption of fecal calprotectin as a non-invasive biomarker for gastrointestinal inflammation assessment. The market is projected to create an absolute opportunity of USD 43.8 billion between 2026 and 2036, driven by expanding use beyond specialist gastroenterology into primary care settings.

ELISA test kits dominate at 58.0%, providing quantitative calprotectin measurement for clinical laboratory analysis. Rapid lateral flow tests are gaining share for point-of-care use in gastroenterology clinics and primary care practices where same-visit results support immediate clinical decision-making. Automated immunoassay platforms integrated with laboratory information systems serve high-throughput hospital laboratories.

IBD diagnosis and treatment monitoring represent the primary clinical applications, where serial calprotectin measurements track disease activity, predict relapse, and assess treatment response without invasive endoscopic procedures. The differential diagnosis of IBS versus IBD in primary care settings is expanding the test utilization rate as clinical guidelines standardize calprotectin screening in the GI symptom evaluation pathway.

Market Segmentation Analysis

• Calprotectin ELISA test kits hold 58.0% of the product segment, with quantitative immunoassay formats serving clinical laboratories and hospital diagnostic departments.
• IBD diagnosis and monitoring accounts for the largest application, with serial calprotectin testing tracking disease activity and treatment response.
• Rapid lateral flow tests are the fastest-growing product category as point-of-care demand expands in gastroenterology and primary care settings.

The calprotectin testing market segments by product type, sample type, application, technology, end use, and distribution channel. ELISA kits lead the product segment, while fecal sample testing dominates. IBD diagnosis and monitoring is the primary application. Healthcare providers are the largest end users.

Insights into the Calprotectin ELISA Test Kits Segment

ELISA test kits hold 58.0% of the product segment in 2026, serving as the reference standard for quantitative fecal calprotectin measurement. Laboratory-based ELISA provides precise calprotectin quantification in micrograms per gram, enabling clinicians to assess inflammation severity, set treatment thresholds, and monitor disease activity over time.

Automated immunoassay platforms that integrate calprotectin testing into multi-analyte laboratory workflows are gaining adoption in high-throughput hospital laboratories. Point-of-care rapid tests using lateral flow immunochromatography provide semi-quantitative results within 15 to 30 minutes, supporting clinic-based screening and treatment monitoring.

Insights into the IBD Diagnosis and Monitoring Application Segment

IBD diagnosis and monitoring is the largest application for calprotectin testing. Elevated fecal calprotectin levels above 50 to 200 micrograms per gram indicate intestinal inflammation, distinguishing IBD from functional gastrointestinal disorders such as IBS. Serial testing tracks disease activity, predicts relapse, and assesses biological therapy response.

Primary care screening using calprotectin reduces unnecessary colonoscopy referrals by identifying patients with low calprotectin levels who are unlikely to have IBD. This application is expanding as clinical guidelines standardize calprotectin testing in the GI symptom evaluation pathway across healthcare systems.

Calprotectin Testing Market Drivers, Restraints, and Opportunities

• Clinical guideline adoption is creating structured demand as gastroenterology and primary care practice standards incorporate fecal calprotectin testing into GI symptom evaluation pathways.
• Assay standardization challenges across different manufacturer platforms create clinical interpretation variability that limits cross-platform result comparability.
• IBD prevalence growth and the clinical need for non-invasive treatment monitoring are creating sustained testing volume growth.

The calprotectin testing market is shaped by clinical guideline adoption, non-invasive diagnostic trends, and IBD prevalence growth. Growth is constrained by assay standardization challenges, while opportunities exist in primary care screening expansion, point-of-care testing, and treatment monitoring applications.

Clinical Guideline Standardization

Demand is shaped by clinical practice guideline endorsement from AGA, ACG, ECCO, and NICE that recommend fecal calprotectin testing as a first-line non-invasive tool for GI symptom evaluation. Guideline adoption creates structured procurement as healthcare systems incorporate calprotectin into standard diagnostic pathways.

Assay Standardization Variability

Growth is constrained by the lack of universal standardization across calprotectin assay platforms from different manufacturers. Variability in extraction methods, antibody specificity, and calibrator traceability affects result comparability across laboratories, complicating serial monitoring when patients are tested at different facilities.

Primary Care Screening Expansion

Adoption is increasing as calprotectin testing moves beyond specialist gastroenterology into primary care settings where GPs use the test to screen patients presenting with GI symptoms before deciding on specialist referral. This expansion significantly broadens the test utilization rate and addressable market volume.

Analysis of Calprotectin Testing Market By Key Countries

Country	CAGR
USA	6%
UK	5.4%
EU	5.6%
Japan	5.3%
South Korea	5.8%

• The USA leads at 6.0% CAGR, driven by clinical guideline adoption, insurance coverage expansion, and growing primary care utilization.
• South Korea at 5.8% reflects expanding gastroenterology infrastructure and increasing adoption of non-invasive diagnostic biomarkers.
• The EU at 5.6% shows growth from ECCO guideline endorsement and national health system procurement standardization.

The global calprotectin testing market is projected to grow at 6.1% CAGR from 2026 to 2036. The study covers more than 30 countries, and the main markets are listed below.

Demand Outlook for Calprotectin Testing Market in the United States

The US market leads at 6.0% CAGR through 2036. AGA and ACG clinical guideline endorsement, expanding health insurance coverage, and growing primary care utilization sustain procurement. CMS coverage decisions for fecal calprotectin testing support adoption across Medicare and Medicaid patient populations.

• AGA and ACG guideline endorsement creates standardized clinical demand for calprotectin testing in GI symptom evaluation.
• Health insurance coverage expansion supports patient access to calprotectin testing across commercial and government programs.
• Primary care adoption is broadening test utilization beyond specialist gastroenterology into general practice screening.

Future Outlook for Calprotectin Testing Market in the United Kingdom

The UK market grows at 5.4% CAGR through 2036. NICE guideline endorsement of calprotectin testing for IBS and IBD differentiation sustains procurement across NHS laboratories and GP practices. Cost-effectiveness evidence supports continued NHS funding for calprotectin testing as an alternative to colonoscopy referral.

• NICE guideline endorsement creates standardized calprotectin testing procurement across NHS hospital laboratories and GP practices.
• Cost-effectiveness evidence supporting colonoscopy avoidance sustains NHS funding and formulary inclusion for calprotectin assays.
• Point-of-care rapid test adoption in GP practices enables same-visit clinical decisions for GI symptom presentation.

Opportunity Analysis for Calprotectin Testing Market in the EU

The EU market grows at 5.6% CAGR through 2036. ECCO clinical guidelines and national health system procurement standardization support calprotectin testing adoption across EU member states. German, French, and Scandinavian health systems lead EU adoption with established laboratory testing infrastructure.

• ECCO guideline endorsement creates harmonized clinical demand across EU gastroenterology and primary care settings.
• National health system procurement standardization supports structured calprotectin test kit purchasing across EU markets.
• Laboratory automation integration enables high-throughput calprotectin testing in EU hospital diagnostic departments.

In-depth Analysis of Calprotectin Testing Market in Japan

Japan grows at 5.3% CAGR through 2036. Expanding gastroenterology practice infrastructure, growing IBD prevalence, and adoption of non-invasive diagnostic approaches sustain demand. Japanese clinical practice emphasizes precision diagnostics, favoring quantitative ELISA-based calprotectin assays.

• Growing IBD prevalence in the Japanese population creates expanding clinical demand for calprotectin testing.
• Precision diagnostic culture in Japanese medicine favors quantitative ELISA platforms with high analytical accuracy.
• Gastroenterology practice infrastructure expansion supports broader adoption of calprotectin testing in hospital and clinic settings.

Sales Analysis for Calprotectin Testing Market in South Korea

South Korea grows at 5.8% CAGR through 2036. Expanding gastroenterology infrastructure, health system modernization, and increasing adoption of non-invasive biomarker testing sustain demand. Korean health insurance coverage for diagnostic testing supports patient access to calprotectin assays.

• Health system modernization supports adoption of standardized non-invasive biomarker testing in gastroenterology practice.
• Health insurance coverage for diagnostic testing enables patient access to calprotectin assays across hospital and clinic settings.
• Growing gastroenterology specialist workforce supports clinical adoption and utilization of calprotectin testing protocols.

Competitive Landscape and Strategic Positioning

• BUHLMANN Laboratories AG leads as the originator of the fCAL calprotectin platform with established clinical validation and global laboratory distribution.
• Thermo Fisher Scientific and DiaSorin S.p.A. maintain strong positions in immunoassay platforms with calprotectin testing menus for high-throughput laboratories.
• Roche Diagnostics and Abbott Laboratories compete on automated diagnostic platforms integrating calprotectin into multi-analyte laboratory workflows.

The competitive landscape spans specialized calprotectin assay developers and large-scale diagnostic platform companies. BUHLMANN Laboratories leads with the fCAL platform, the most widely validated calprotectin assay globally. Thermo Fisher Scientific and DiaSorin offer calprotectin testing on their immunoassay platforms. Roche Diagnostics and Abbott integrate calprotectin into automated multi-analyte laboratory systems.

Biohit Oyj and Biomerica serve the point-of-care rapid test segment. Eurofins Scientific and Quest Diagnostics offer calprotectin testing as laboratory services. Competition centers on assay analytical performance, clinical validation data, laboratory automation compatibility, and regulatory market access.

Entry barriers include clinical validation requirements, regulatory approval timelines, laboratory platform integration complexity, and the need for established clinical reference data supporting test clinical utility.

Key Companies in the Calprotectin Testing Market

Key global companies leading the calprotectin testing market include:

• BUHLMANN Laboratories AG (Switzerland), Thermo Fisher Scientific (USA), and DiaSorin S.p.A. (Italy) lead with validated calprotectin assay platforms, clinical evidence portfolios, and global laboratory distribution.
• Roche Diagnostics (Switzerland) and Abbott Laboratories (USA) hold strong positions through automated immunoassay platform integration with calprotectin testing menus.
• Biohit Oyj (Finland), Biomerica Inc. (USA), and Alere Inc. (USA) are gaining traction in point-of-care rapid calprotectin testing for clinic-based screening applications.

Competitive Benchmarking: Calprotectin Testing Market

Company	Assay Validation	Lab Automation	POC Testing	Geographic Reach
BUHLMANN Laboratories	High	Medium	Medium	Global
Thermo Fisher Scientific	High	High	Low	Global
DiaSorin S.p.A.	High	High	Low	Global
Roche Diagnostics	High	High	Low	Global
Abbott Laboratories	High	High	Medium	Global
Biohit Oyj	Medium	Low	High	Europe
Biomerica Inc.	Medium	Low	High	North America
Eurofins Scientific	High	High	Low	Europe

Source: Future Market Insights competitive analysis, 2026.

Key Developments in Calprotectin Testing Market

• In 2025, BUHLMANN Laboratories AG launched an updated fCAL turbo assay with improved precision and shorter incubation time for high-throughput laboratory applications.
• In 2025, Abbott Laboratories expanded calprotectin testing availability on its automated immunoassay platforms for hospital laboratory deployment in North American and European markets.

Key Players in the Calprotectin Testing Market

Major Global Players

• BUHLMANN Laboratories AG
• Thermo Fisher Scientific
• DiaSorin S.p.A.
• Roche Diagnostics
• Abbott Laboratories

Emerging Players/Startups

• Certest Biotec
• PhiCal (Calpro AS)

Report Scope and Coverage

Parameter	Details
Market size by 2036	USD 98.1 billion
Growth rate	6.1% CAGR (2026 to 2036)
Forecast period	2026 to 2036
Base year value (2025)	USD 51.1 billion
Key Segment Covered	Product, Sample, Application, Technology, End Use, Distribution Channel
Regions covered	North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia and Pacific, Middle East and Africa
Countries covered	USA, South Korea, UK, Japan, Germany, 30 plus countries
Key companies profiled	BUHLMANN Laboratories AG, Thermo Fisher Scientific, DiaSorin S.p.A., Roche Diagnostics, Abbott Laboratories, Biohit Oyj, Biomerica Inc., Eurofins Scientific
Approach	Hybrid bottom-up and top-down methodology starting with verified transaction data, projecting adoption velocity across segments and regions.

Market Segmentation Analysis

Calprotectin Testing Market Segmented by Product:

• Calprotectin ELISA Test Kits
  • Microplate ELISA Kits
    • 96 Well ELISA Kits
    • 384 Well ELISA Kits
  • Automated ELISA Kits
    • High Throughput ELISA Systems
    • Laboratory Automation Compatible Kits
• Calprotectin Rapid Testing Kits
  • Lateral Flow Assays
    • Cassette Based Rapid Tests
    • Strip Based Rapid Tests
  • Point of Care Immunoassays
    • Portable Reader Based Systems
    • Reader Free Rapid Systems
• Immunofluorescence Assays
  • Fluorescence Analyzer Based Tests
    • Desktop Analyzer Systems
    • Portable Analyzer Systems
  • Chemiluminescence Assays
    • High Sensitivity Assays
    • Multiplex Assays
• Quantitative Immunochromatography
  • Laboratory Quantitative Systems
    • Automated Quantification Platforms
    • Semi Automated Quantification Platforms
  • Point of Care Quantification
    • Clinic Based Systems
    • Home Monitoring Systems

Calprotectin Testing Market Segmented by Sample:

• Stool Samples
  • Fresh Stool Samples
    • Routine Diagnostic Samples
    • Inflammatory Disease Monitoring Samples
  • Preserved Stool Samples
    • Buffered Preservation Samples
    • Transport Medium Samples
• Blood Serum and Plasma
  • Serum Samples
    • Inflammatory Marker Panels
    • Hospital Laboratory Samples
  • Plasma Samples
    • EDTA Plasma Samples
    • Heparin Plasma Samples
• Other Biological Samples
  • Urine Samples
    • Experimental Biomarker Analysis
    • Research Use Samples
  • Saliva Samples
    • Screening Applications
    • Non Invasive Research Applications

Calprotectin Testing Market Segmented by Application:

• Inflammatory Bowel Disease
  • Crohn’s Disease
    • Active Disease Monitoring
    • Treatment Response Monitoring
  • Ulcerative Colitis
    • Disease Severity Assessment
    • Remission Monitoring
• Irritable Bowel Syndrome
  • Primary Screening
    • Differential Diagnosis
    • Outpatient Screening
  • Functional Gastrointestinal Assessment
    • Primary Care Screening
    • Referral Screening
• Colorectal Cancer
  • Early Detection Support
    • High Risk Population Screening
    • Post Treatment Monitoring
  • Cancer Recurrence Monitoring
    • Routine Surveillance
    • Oncology Follow Up
• Other Gastrointestinal Disorders
  • Celiac Disease
    • Gluten Sensitivity Assessment
    • Inflammatory Screening
  • Gastrointestinal Infections
    • Bacterial Gastroenteritis
    • Chronic Intestinal Inflammation

Calprotectin Testing Market Segmented by Technology:

• Enzyme Linked Immunosorbent Assay
  • Manual ELISA Platforms
    • Standard Laboratory Testing
    • Batch Processing Workflows
  • Automated ELISA Platforms
    • Integrated Laboratory Systems
    • High Volume Processing
• Rapid Immunochromatographic Assays
  • Lateral Flow Technology
    • Visual Detection Systems
    • Digital Reader Systems
  • Quantitative Rapid Assays
    • Portable Quantification Systems
    • Clinic Based Quantification
• Fluoroimmunoassay
  • Fluorescent Detection Systems
    • High Sensitivity Detection
    • Multiplex Fluorescence Platforms
  • Automated Fluorescence Platforms
    • Central Laboratory Systems
    • Reference Laboratory Systems
• Chemiluminescence Immunoassay
  • High Sensitivity Chemiluminescence
    • Hospital Laboratory Systems
    • Specialized Diagnostic Systems
  • Multiparameter Immunoassays
    • Integrated Biomarker Panels
    • Advanced Diagnostic Platforms

Calprotectin Testing Market Segmented by End Use:

• Hospitals
  • Public Hospitals
    • Government Healthcare Systems
    • University Hospitals
  • Private Hospitals
    • Multi Specialty Hospitals
    • Corporate Hospital Networks
• Diagnostic Laboratories
  • Independent Diagnostic Laboratories
    • Central Reference Laboratories
    • Regional Diagnostic Chains
  • Hospital Affiliated Laboratories
    • Integrated Hospital Networks
    • Academic Medical Laboratories
• Specialty Clinics
  • Gastroenterology Clinics
    • Inflammatory Bowel Disease Centers
    • Digestive Disease Clinics
  • Oncology Clinics
    • Colorectal Cancer Clinics
    • Preventive Oncology Centers
• Academic and Research Institutes
  • Clinical Research Institutes
    • Biomarker Research Programs
    • Inflammatory Disease Studies
  • Academic Laboratories
    • University Research Centers
    • Translational Research Programs

Calprotectin Testing Market Segmented by Distribution Channel:

• Direct Sales
  • Manufacturer Direct Sales
    • Hospital Procurement Contracts
    • Laboratory Procurement Agreements
  • Inside Sales Teams
    • Institutional Sales Programs
    • Key Account Management
• Distributor Sales
  • Medical Device Distributors
    • National Distribution Networks
    • Regional Distribution Partners
  • Diagnostic Product Suppliers
    • Integrated Laboratory Suppliers
    • Specialty Diagnostic Suppliers
• Online Sales
  • E Procurement Platforms
    • Hospital Procurement Portals
    • Laboratory Procurement Platforms
  • Third Party Marketplaces
    • Medical Supply Platforms
    • Diagnostic Product Marketplaces

Calprotectin Testing Market by Region:

• North America
  • USA
  • Canada
  • Mexico
• Latin America
  • Brazil
  • Chile
  • Rest of Latin America
• Western Europe
  • Germany
  • UK
  • Italy
  • Spain
  • France
  • Nordic
  • BENELUX
  • Rest of Western Europe
• Eastern Europe
  • Russia
  • Poland
  • Hungary
  • Balkan & Baltic
  • Rest of Eastern Europe
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia & New Zealand
  • Rest of South Asia and Pacific
• Middle East & Africa
  • Kingdom of Saudi Arabia
  • Other GCC Countries
  • Türkiye
  • South Africa
  • Other African Union
  • Rest of Middle East & Africa

Research Sources and Bibliography

• 1. American Gastroenterological Association. (2025). AGA Clinical Practice Guideline: Fecal Calprotectin Testing in GI Symptom Evaluation. AGA.
• 2. National Institute for Health and Care Excellence. (2025). NICE Diagnostics Guidance: Faecal Calprotectin Testing for IBD. NICE.
• 3. European Crohn's and Colitis Organisation. (2025). ECCO Guidelines on Diagnostic Approach to IBD. ECCO.
• 4. World Health Organization. (2025). WHO Global Report on Inflammatory Bowel Disease Prevalence and Management. WHO.
• 5. BUHLMANN Laboratories AG. (2025). fCAL Calprotectin Assay Platform: Clinical Validation and Performance Data. BUHLMANN.

This bibliography is provided for reader reference.

This Report Answers

• Estimating the size of the market and how much revenue it is projected to generate from 2026 to 2036.
• Segmentation by product, sample, application, technology, end use, distribution channel.
• Insights about more than 30 markets in the region.
• Analysis of product types including ELISA kits, rapid lateral flow tests, and automated immunoassay platforms.
• Assessment of the competitive landscape.
• Finding investment opportunities in IBD diagnosis, primary care screening, treatment monitoring, and point-of-care testing.
• Keeping track of the supply chain.
• Delivery of data in PDF and Excel formats.